Cross-Neutralizing and Protective Human Antibody Specificities to Poxvirus Infections

Iuliia Gilchuk, Pavlo Gilchuk, Gopal Sapparapu, Rebecca Lampley, Vidisha Singh, Nurgun Kose, David L. Blum, Laura J. Hughes, Panayampalli S. Satheshkumar, Michael B. Townsend, Ashley V. Kondas, Zachary Reed, Zachary Weiner, Victoria A. Olson, Erika Hammarlund, Hans Peter Raue, Mark Slifka, James C. Slaughter, Barney S. Graham, Kathryn M. EdwardsRoselyn J. Eisenberg, Gary H. Cohen, Sebastian Joyce, James E. Crowe

    Research output: Contribution to journalArticle

    15 Citations (Scopus)

    Abstract

    Monkeypox (MPXV) and cowpox (CPXV) are emerging agents that cause severe human infections on an intermittent basis, and variola virus (VARV) has potential for use as an agent of bioterror. Vaccinia immune globulin (VIG) has been used therapeutically to treat severe orthopoxvirus infections but is in short supply. We generated a large panel of orthopoxvirus-specific human monoclonal antibodies (Abs) from immune subjects to investigate the molecular basis of broadly neutralizing antibody responses for diverse orthopoxviruses. Detailed analysis revealed the principal neutralizing antibody specificities that are cross-reactive for VACV, CPXV, MPXV, and VARV and that are determinants of protection in murine challenge models. Optimal protection following respiratory or systemic infection required a mixture of Abs that targeted several membrane proteins, including proteins on enveloped and mature virion forms of virus. This work reveals orthopoxvirus targets for human Abs that mediate cross-protective immunity and identifies new candidate Ab therapeutic mixtures to replace VIG.

    Original languageEnglish (US)
    Pages (from-to)684-694.e9
    JournalCell
    Volume167
    Issue number3
    DOIs
    StatePublished - Oct 20 2016

    Fingerprint

    Poxviridae Infections
    Orthopoxvirus
    Antibody Specificity
    Viruses
    Variola virus
    Neutralizing Antibodies
    Vaccinia
    Antibodies
    Immunoglobulins
    Monkeypox
    Cowpox
    Infection
    Membrane Proteins
    Monoclonal Antibodies
    Virion
    Antibody Formation
    Immunity
    Proteins

    Keywords

    • antigen specificity
    • cross-neutralization
    • human monoclonal antibodies
    • poxvirus infections
    • protective immunity
    • smallpox vaccine

    ASJC Scopus subject areas

    • Biochemistry, Genetics and Molecular Biology(all)

    Cite this

    Gilchuk, I., Gilchuk, P., Sapparapu, G., Lampley, R., Singh, V., Kose, N., ... Crowe, J. E. (2016). Cross-Neutralizing and Protective Human Antibody Specificities to Poxvirus Infections. Cell, 167(3), 684-694.e9. https://doi.org/10.1016/j.cell.2016.09.049

    Cross-Neutralizing and Protective Human Antibody Specificities to Poxvirus Infections. / Gilchuk, Iuliia; Gilchuk, Pavlo; Sapparapu, Gopal; Lampley, Rebecca; Singh, Vidisha; Kose, Nurgun; Blum, David L.; Hughes, Laura J.; Satheshkumar, Panayampalli S.; Townsend, Michael B.; Kondas, Ashley V.; Reed, Zachary; Weiner, Zachary; Olson, Victoria A.; Hammarlund, Erika; Raue, Hans Peter; Slifka, Mark; Slaughter, James C.; Graham, Barney S.; Edwards, Kathryn M.; Eisenberg, Roselyn J.; Cohen, Gary H.; Joyce, Sebastian; Crowe, James E.

    In: Cell, Vol. 167, No. 3, 20.10.2016, p. 684-694.e9.

    Research output: Contribution to journalArticle

    Gilchuk, I, Gilchuk, P, Sapparapu, G, Lampley, R, Singh, V, Kose, N, Blum, DL, Hughes, LJ, Satheshkumar, PS, Townsend, MB, Kondas, AV, Reed, Z, Weiner, Z, Olson, VA, Hammarlund, E, Raue, HP, Slifka, M, Slaughter, JC, Graham, BS, Edwards, KM, Eisenberg, RJ, Cohen, GH, Joyce, S & Crowe, JE 2016, 'Cross-Neutralizing and Protective Human Antibody Specificities to Poxvirus Infections', Cell, vol. 167, no. 3, pp. 684-694.e9. https://doi.org/10.1016/j.cell.2016.09.049
    Gilchuk I, Gilchuk P, Sapparapu G, Lampley R, Singh V, Kose N et al. Cross-Neutralizing and Protective Human Antibody Specificities to Poxvirus Infections. Cell. 2016 Oct 20;167(3):684-694.e9. https://doi.org/10.1016/j.cell.2016.09.049
    Gilchuk, Iuliia ; Gilchuk, Pavlo ; Sapparapu, Gopal ; Lampley, Rebecca ; Singh, Vidisha ; Kose, Nurgun ; Blum, David L. ; Hughes, Laura J. ; Satheshkumar, Panayampalli S. ; Townsend, Michael B. ; Kondas, Ashley V. ; Reed, Zachary ; Weiner, Zachary ; Olson, Victoria A. ; Hammarlund, Erika ; Raue, Hans Peter ; Slifka, Mark ; Slaughter, James C. ; Graham, Barney S. ; Edwards, Kathryn M. ; Eisenberg, Roselyn J. ; Cohen, Gary H. ; Joyce, Sebastian ; Crowe, James E. / Cross-Neutralizing and Protective Human Antibody Specificities to Poxvirus Infections. In: Cell. 2016 ; Vol. 167, No. 3. pp. 684-694.e9.
    @article{f9ffb1978c6946a5904914572c341b90,
    title = "Cross-Neutralizing and Protective Human Antibody Specificities to Poxvirus Infections",
    abstract = "Monkeypox (MPXV) and cowpox (CPXV) are emerging agents that cause severe human infections on an intermittent basis, and variola virus (VARV) has potential for use as an agent of bioterror. Vaccinia immune globulin (VIG) has been used therapeutically to treat severe orthopoxvirus infections but is in short supply. We generated a large panel of orthopoxvirus-specific human monoclonal antibodies (Abs) from immune subjects to investigate the molecular basis of broadly neutralizing antibody responses for diverse orthopoxviruses. Detailed analysis revealed the principal neutralizing antibody specificities that are cross-reactive for VACV, CPXV, MPXV, and VARV and that are determinants of protection in murine challenge models. Optimal protection following respiratory or systemic infection required a mixture of Abs that targeted several membrane proteins, including proteins on enveloped and mature virion forms of virus. This work reveals orthopoxvirus targets for human Abs that mediate cross-protective immunity and identifies new candidate Ab therapeutic mixtures to replace VIG.",
    keywords = "antigen specificity, cross-neutralization, human monoclonal antibodies, poxvirus infections, protective immunity, smallpox vaccine",
    author = "Iuliia Gilchuk and Pavlo Gilchuk and Gopal Sapparapu and Rebecca Lampley and Vidisha Singh and Nurgun Kose and Blum, {David L.} and Hughes, {Laura J.} and Satheshkumar, {Panayampalli S.} and Townsend, {Michael B.} and Kondas, {Ashley V.} and Zachary Reed and Zachary Weiner and Olson, {Victoria A.} and Erika Hammarlund and Raue, {Hans Peter} and Mark Slifka and Slaughter, {James C.} and Graham, {Barney S.} and Edwards, {Kathryn M.} and Eisenberg, {Roselyn J.} and Cohen, {Gary H.} and Sebastian Joyce and Crowe, {James E.}",
    year = "2016",
    month = "10",
    day = "20",
    doi = "10.1016/j.cell.2016.09.049",
    language = "English (US)",
    volume = "167",
    pages = "684--694.e9",
    journal = "Cell",
    issn = "0092-8674",
    publisher = "Cell Press",
    number = "3",

    }

    TY - JOUR

    T1 - Cross-Neutralizing and Protective Human Antibody Specificities to Poxvirus Infections

    AU - Gilchuk, Iuliia

    AU - Gilchuk, Pavlo

    AU - Sapparapu, Gopal

    AU - Lampley, Rebecca

    AU - Singh, Vidisha

    AU - Kose, Nurgun

    AU - Blum, David L.

    AU - Hughes, Laura J.

    AU - Satheshkumar, Panayampalli S.

    AU - Townsend, Michael B.

    AU - Kondas, Ashley V.

    AU - Reed, Zachary

    AU - Weiner, Zachary

    AU - Olson, Victoria A.

    AU - Hammarlund, Erika

    AU - Raue, Hans Peter

    AU - Slifka, Mark

    AU - Slaughter, James C.

    AU - Graham, Barney S.

    AU - Edwards, Kathryn M.

    AU - Eisenberg, Roselyn J.

    AU - Cohen, Gary H.

    AU - Joyce, Sebastian

    AU - Crowe, James E.

    PY - 2016/10/20

    Y1 - 2016/10/20

    N2 - Monkeypox (MPXV) and cowpox (CPXV) are emerging agents that cause severe human infections on an intermittent basis, and variola virus (VARV) has potential for use as an agent of bioterror. Vaccinia immune globulin (VIG) has been used therapeutically to treat severe orthopoxvirus infections but is in short supply. We generated a large panel of orthopoxvirus-specific human monoclonal antibodies (Abs) from immune subjects to investigate the molecular basis of broadly neutralizing antibody responses for diverse orthopoxviruses. Detailed analysis revealed the principal neutralizing antibody specificities that are cross-reactive for VACV, CPXV, MPXV, and VARV and that are determinants of protection in murine challenge models. Optimal protection following respiratory or systemic infection required a mixture of Abs that targeted several membrane proteins, including proteins on enveloped and mature virion forms of virus. This work reveals orthopoxvirus targets for human Abs that mediate cross-protective immunity and identifies new candidate Ab therapeutic mixtures to replace VIG.

    AB - Monkeypox (MPXV) and cowpox (CPXV) are emerging agents that cause severe human infections on an intermittent basis, and variola virus (VARV) has potential for use as an agent of bioterror. Vaccinia immune globulin (VIG) has been used therapeutically to treat severe orthopoxvirus infections but is in short supply. We generated a large panel of orthopoxvirus-specific human monoclonal antibodies (Abs) from immune subjects to investigate the molecular basis of broadly neutralizing antibody responses for diverse orthopoxviruses. Detailed analysis revealed the principal neutralizing antibody specificities that are cross-reactive for VACV, CPXV, MPXV, and VARV and that are determinants of protection in murine challenge models. Optimal protection following respiratory or systemic infection required a mixture of Abs that targeted several membrane proteins, including proteins on enveloped and mature virion forms of virus. This work reveals orthopoxvirus targets for human Abs that mediate cross-protective immunity and identifies new candidate Ab therapeutic mixtures to replace VIG.

    KW - antigen specificity

    KW - cross-neutralization

    KW - human monoclonal antibodies

    KW - poxvirus infections

    KW - protective immunity

    KW - smallpox vaccine

    UR - http://www.scopus.com/inward/record.url?scp=84992677658&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84992677658&partnerID=8YFLogxK

    U2 - 10.1016/j.cell.2016.09.049

    DO - 10.1016/j.cell.2016.09.049

    M3 - Article

    C2 - 27768891

    AN - SCOPUS:84992677658

    VL - 167

    SP - 684-694.e9

    JO - Cell

    JF - Cell

    SN - 0092-8674

    IS - 3

    ER -